Wei “Vivian” Wang, Ph.D., in the department of pharmaceutical outcomes and policy and Haesuk Park, Ph.D., an associate professor in the department, led the study.
Featured: Cody Wiberg, Pharm.D., M.S.
Lo-Ciganic’s talk on Sept. 3 will focus on the application of advanced analytics in pharmaceutical outcomes research.
Lo-Ciganic received the award for her paper published in JAMA Network Open that reported on her and her co-authors’ investigation of five different machine learning approaches to predict opioid overdose.
Dr. Hincapie-Castillo has been appointed as a consultant to the FDA's Drug Safety and Risk Management Advisory Committee.
Researchers in the UF College of Pharmacy published the study in JAMA and used a commercial insurance database to examine the trends in the prescribing of preexposure prophylaxis for HIV prevention in the U.S.
Hartzema's study will evaluate a novel software tool developed to inform opioid prescribers of patient risks and therapy benefits.
Weihsuan “Jenny” Lo-Ciganic, Ph.D., M.S., M.S.Pharm., will lead a short course workshop on machine learning as part of the International Society for Pharmacoeconomics and Outcomes Research’s Virtual ISPOR 2020 Conference from 10 a.m. to 3 p.m. EST on Monday, July 27. Weishuan “Jenny” Lo-Ciganic, Ph.D., M.S., M.S.Pharm. Lo-Ciganic, as assistant professor in…
Is the off-brand Tylenol really the same? Will every name brand drug eventually have a generic version? What should you keep in mind when considering name brand versus generic drugs?
The findings are published in July’s issue of Clinical Pharmacology and Therapeutics, the flagship journal of the American Society of Clinical Pharmacology and Therapeutics.